| Patents for A61P 43 - Drugs for specific purposes, not provided for in groups (156,317) |
|---|
| 03/04/2010 | CA2733648A1 Novel pyrrole derivative having, as substituents, ureide group, aminocarbonyl group and bicyclic group which may have substituent |
| 03/03/2010 | EP2159230A1 Anti-TNF antibodies, compositions, methods and uses |
| 03/03/2010 | EP2159216A1 Ih - Modulators |
| 03/03/2010 | EP2158907A2 A composition for use as a medicament for topical application to skin |
| 03/03/2010 | EP1743648B1 Method for treating inflammation |
| 03/03/2010 | EP1505973B1 Combinations for treating multiple myeloma |
| 03/03/2010 | EP1496920B1 Pharmaceutical composition containing an extract from barleria prionitis linn and its process of preparation |
| 03/03/2010 | EP1419179B1 Antigen binding domains from fish |
| 03/03/2010 | EP1389183B1 Sulfonamide derivatives |
| 03/03/2010 | EP1386908B1 Amine derivative with potassium channel regulatory function, its preparation and use |
| 03/03/2010 | EP1107964B1 Isoquinoline derivatives with angiogenesis inhibiting activity |
| 03/03/2010 | EP0852499B1 Therapeutic azide compounds |
| 03/03/2010 | CN101661501A Method of forming molecule function network |
| 03/03/2010 | CN100592905C Pet food composition for skin photoprotection |
| 03/02/2010 | US7671180 Heparin binding protein for use in diagnosis, prvention and treatment of cell proliferative, liver, neurodegeneartive, inflammatory and pancreatic disorders; wound healing agents |
| 03/02/2010 | US7671092 Paclitaxel enhancer compounds |
| 03/02/2010 | US7671087 Amines that inhibit a mammalian anandamide transporter, and methods of use thereof |
| 03/02/2010 | US7671075 Therapy and prophylaxis of Alzheimer's Disease and Down's syndrome; inhibiting beta amyloid production; 2,4-difluoro-N-[(1S,2S)-1-(hydroxymethyl)-2-methylbutyl]benzenesulfonamide |
| 03/02/2010 | US7671071 Crystal structure; antihistamines; histamine H1-antagonists; side effect reduction; storage stability |
| 03/02/2010 | US7671035 Epidermal growth factor receptor antisense oligonucleotides |
| 03/02/2010 | US7670791 regulating an alpha 1G T-type calcium channel in the central nervous system and alpha 1H and alpha 1I T-type calcium channels in the peripheral nervous system; analegesic |
| 03/02/2010 | US7670632 Saponin mixtures and compounds isolated from Acacia victoriae; glycosides of acacic or oleanolic acid; control of cell apoptosis and cytotoxicity; antitumor, -carcinogenic, -inflammatory and -proliferative agents; atherosclerosis |
| 03/02/2010 | CA2394615C Substituted 1,3,4-oxadiazoles and a method of reducing tnf-.alpha. levels |
| 02/25/2010 | WO2010021412A1 Therapeutic material for cerebral infarction, and method for regeneration of brain tissue |
| 02/25/2010 | WO2010021385A1 Therapeutic agent for anca-related vasculitis |
| 02/25/2010 | WO2010021381A1 Fused heterocyclic derivative and use thereof |
| 02/25/2010 | WO2010021351A1 Cycloalkylamine derivative |
| 02/25/2010 | WO2010021247A1 Pharmaceutical preparation, food or beverage having inhibitory activity on serotonin transporter |
| 02/25/2010 | WO2010021149A1 Spiro compound capable of inhibiting acid secretion |
| 02/25/2010 | WO2010021129A1 Apoptosis inhibitor |
| 02/25/2010 | WO2010020703A1 Mek 1/2 inhibitors for the treatment of peritoneal fibrosis |
| 02/25/2010 | WO2010020593A1 Treatment of an autoimmune disease using il-18 antagonists |
| 02/25/2010 | WO2010020198A1 A composition for making pathological tissues dehydration and/or contraction |
| 02/25/2010 | WO2009129205A3 Sparc anti-inflammatory activity and uses thereof |
| 02/25/2010 | WO2002068414A8 Analogs of thalidomide as potential angiogenesis inhibitors |
| 02/25/2010 | US20100050281 Identification of Genes and Their Products Which Promote Hybrid Vigour or Hybrid Debility and Uses Thereof |
| 02/25/2010 | US20100049491 Method and System for Optimizing Minigenes and Peptides Encoded Thereby |
| 02/25/2010 | US20100048737 Cosmetic preparations based on molecularly imprinted polymers |
| 02/25/2010 | US20100048736 Anionic charge-dynamic polymers for release of cationic agents |
| 02/25/2010 | US20100048735 Polyaminoacids functionalized wtih alpha-tocopherol, and uses thereof, especially therapeutic uses |
| 02/25/2010 | US20100048717 Cathepsin b inhibitors |
| 02/25/2010 | US20100048707 Polymeric Reagents Comprising a Terminal Vinylic Group and Conjugates Formed Therefrom |
| 02/25/2010 | US20100048698 Macrocyclic diterpenes for treating conditions associated with protein kinase c |
| 02/25/2010 | US20100048695 Anti-fatigue agent |
| 02/25/2010 | US20100048689 Process of obtainment of soy isoflavones |
| 02/25/2010 | US20100048670 Stable and Long-Lasting siRNA Expression Vectors and the Applications Thereof |
| 02/25/2010 | US20100048659 Aqueous compositions containing metronidazole |
| 02/25/2010 | US20100048654 Use of valsartan or its metabolite to in hibit platelet aggregation |
| 02/25/2010 | US20100048626 Aryl Substituted Pyridines and the Use Thereof |
| 02/25/2010 | US20100048613 Polymorphic form of granisetron hydrochloride and methods of making the same |
| 02/25/2010 | US20100048590 N-(3-amino-2-hydroxy-propyl) substituted alkylamide compounds |
| 02/25/2010 | US20100048588 Aminocarbonyl-derivatives as novel inhibitors of histone deacetylase |
| 02/25/2010 | US20100048565 Benzimidazole derivatives |
| 02/25/2010 | US20100048552 such as N-ethyl-3-(9-ethyl-8-oxo-8,9-dihydro-3H-3,4,9-triaza-cyclopenta[a]naphthalen-7-yl)-5-methoxy-benzamide, used to treat or prevent diseases or disorders associated with abnormal or deregulated kinase activity |
| 02/25/2010 | US20100048542 Methods and compositions for treating primary and secondary tumors of the central nervous system (cns) |
| 02/25/2010 | US20100048528 Heterocyclic compounds as inhibitors of beta-lactamases |
| 02/25/2010 | US20100048527 Methods and compositions for the non-surgical removal of fat |
| 02/25/2010 | US20100048512 Radiation protection drug containing tocopherol or tocotrienol compound ester derivative as active ingredient |
| 02/25/2010 | US20100048510 Dissolution of amyloid fibrils by flavonoids and other compounds |
| 02/25/2010 | US20100048502 Bhq-caged nucleotide probes photolysable by two-photon excitation |
| 02/25/2010 | US20100048490 Binding ligand linked drug delivery conjugates of tubulysins |
| 02/25/2010 | US20100048485 Substrates of n-end rule ubiquitylation and methods for measuring the ubiquitylation of these substrate |
| 02/25/2010 | US20100048483 Polymeric benzyl carbonate-derivatives |
| 02/25/2010 | US20100048474 Method of treating or preventing tissue deterioration, injury or damage due to periodontal disease or disease of oral mucosa, and/or downregulating nf-kappabeta or supressing nf-kappabeta-mediated actions |
| 02/25/2010 | US20100048458 Tribonectins |
| 02/25/2010 | US20100048456 Glycopegylation methods and proteins/peptides produced by the methods |
| 02/25/2010 | US20100047818 Diagnosis of carcinomas |
| 02/25/2010 | US20100047372 Antioxidant and physical performance effects of a grape extract |
| 02/25/2010 | US20100047361 Active Principle which is capable of inducing the conversion of inactive TGFb-Latent into active TGFb |
| 02/25/2010 | US20100047359 Stable powder formulation containing a novel anticholinergic agent |
| 02/25/2010 | US20100047349 Stabilized solid preparation |
| 02/25/2010 | US20100047344 Performance enhancing composition and use thereof |
| 02/25/2010 | US20100047337 Pharmaceutical spheroids |
| 02/25/2010 | US20100047333 Modified Peptides and Their Use for the Treatment of Autoimmune Diseases |
| 02/25/2010 | US20100047326 Multiple-Compartment Applicator |
| 02/25/2010 | US20100047318 Ceramic implants affording controlled release of active materials |
| 02/25/2010 | US20100047292 Methods of processing microparticles and compositions produced thereby |
| 02/25/2010 | US20100047285 Anticancer agents using verotoxin variants |
| 02/25/2010 | US20100047265 Active antiangiogenic therapy |
| 02/25/2010 | US20100047255 Novel activation and transfer cascade for ubiquitin |
| 02/25/2010 | US20100047218 Reversible immortalization |
| 02/25/2010 | US20100047217 Differentiated anucleated cells and method for preparing the same |
| 02/25/2010 | DE102008037337A1 Verfahren zur Herstellung von Wirkstoffen, insbesondere Phenolen aus einer Pflanze A process for the preparation of active compounds, in particular phenols from a plant |
| 02/25/2010 | CA2734870A1 Therapeutic agent for anca-related vasculitis |
| 02/25/2010 | CA2734358A1 Treatment of an autoimmune disease using il-18 antagonists |
| 02/24/2010 | EP2157092A1 Remedy for diabetes |
| 02/24/2010 | EP2157090A1 Pyrazinamide compound |
| 02/24/2010 | EP2157084A1 5-phenyl-3-pyridazinone derivative |
| 02/24/2010 | EP2156842A1 Oral composition |
| 02/24/2010 | EP2156833A1 Prophylactic or therapeutic agent for posterior ocular disease comprising non-ergot selective d2 receptor agonist as active ingredient |
| 02/24/2010 | EP2155714A2 Substituted aromatic heterocyclic compounds as fungicides |
| 02/24/2010 | EP2155197A2 Treatment of lysosomal storage diseases |
| 02/24/2010 | EP1742935B1 Polycyclic pyrazines as potassium ion channel modulators |
| 02/24/2010 | EP1465631B1 Pyrimidine a2b selective antagonist compounds, their synthesis and use |
| 02/24/2010 | EP1033979B2 Combination of cyp2a6 enzyme inhibitors and nicotine and their therapeutic use |
| 02/24/2010 | CN101654673A Rna interference mediating small rna molecules |
| 02/24/2010 | CN101654672A Rna interference mediating small rna molecules |
| 02/24/2010 | CN101654479A Mammalian receptor proteins, agents, and methods relating thereto |
| 02/24/2010 | CN101653603A Peptides and antibodies binding to anionic phospholipids and aminophospholipids and their use in treating disease |
| 02/24/2010 | CN100591329C Montelukast granule formulation |